Based on the data for the years 2024 to 2028, the sales percentage of antihypertensive medicine in South Korea remains constant at 0.1% of total sales. This indicates no year-on-year variation in the forecast period. Consequently, the Compound Annual Growth Rate (CAGR) over this period is 0%, reflecting a stable but stagnant market.
Future trends to watch for include advancements in antihypertensive therapies, potential shifts in healthcare policies, and demographic changes such as an aging population. These factors could significantly influence the market dynamics and alter the current forecast of stable sales percentages.
